Pembrolizumab and Olaparib in Cervical Cancer Patients

Part of paid clinical trials in Miami, Florida.

Sponsor
Baptist Health South Florida
Study ID
NCT04483544
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • pembrolizumab — DRUG
    PD-1 inhibitor pembrolizumab, 200mg intravenously (IV) every 3 weeks
  • olaparib — DRUG
    PARP inhibitor olaparib 300 mg orally, twice daily (BID)

Study Details

The study is a non-randomized, open-label phase II clinical trial to test the investigational combination of the drug pembrolizumab with the drug olaparib in patients diagnosed with advanced or recurrent cervical carcinoma after standard chemotherapy.

Key Dates

Start date
Dec 3, 2020
Status verified
Apr 2025
Primary completion
Dec 12, 2024
Completion
Dec 12, 2024

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    PD-1 inhibitor pembrolizumab, in combination with the PARP inhibitor olaparib

Primary Outcome Measure

Immune Overall Response Rate [ Time Frame: 3 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
Miami Cancer InstituteMiamiFlorida33176-
Miami Cancer Institute at PlantationPlantationFlorida33324-

Related coverage on Hipa.ai

Find similar trials in Miami, FL

By condition
Cervical cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Miami Cancer Institute· Miami, FLMiami Cancer Institute at Plantation· Plantation, FL

Related Studies